Dexcom reports Q2 2026 revenue grew 13%
Operating income rose 590 basis points to 24.3% of revenue, and GAAP net income increased to $249.1 million.
See the latest news and media coverage for Dexcom. We track all announcements, press releases, and industry mentions in real time, all in one place.
Manufacturer of continuous glucose monitoring systems
dexcom.comLast updated
In short: Dexcom reported strong 2026 revenue growth, raised its financial outlook, and secured FDA clearance for its pediatric Stelo CGM.
Operating income rose 590 basis points to 24.3% of revenue, and GAAP net income increased to $249.1 million.
The program aims to evaluate AI-powered glucose health and real-world evidence for earlier intervention in prediabetes and Type 2 diabetes.
The system is the longest-lasting and most accurate CGM authorized by Health Canada, offering 15.5 days of real-time glucose readings.
The release is after market close on July 30, 2026, with a conference call at 4:30 p.m. ET.
Dexcom is allowed to use its 15-day glucose monitoring system in Japan for adults; public insurance is expected to enable access.
AMSL Diabetes has issued an urgent Product Correction for the Dexcom G7 iOS App version 2.12 following non-critical alerts potentially not sounding.
Alongside these portfolio moves, Dexcom?s over-the-counter Stelo Glucose Biosensor System received expanded clearance from the U.S. Food and Drug Administration for pediatric use on June...
Dexcom CEO Jake Leach said he is watching for a decision by the federal health insurance program...
Track Dexcom and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.